<DOC>
	<DOCNO>NCT01323855</DOCNO>
	<brief_summary>This two part study compare PK preladenant administer participant CRI PK preladenant administer healthy participant . Part 1 compare PK participant severe CRI healthy participant . Part 2 compare PK participant moderate CRI participant mild CRI healthy participant . The primary hypothesis plasma area concentration-time curve time 0 infinity single dosing ( AUC0-âˆž ) preladenant participant either severe , moderate mild CRI similar match healthy participant .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics ( PK ) Preladenant Participants With Chronic Renal Impairment ( CRI ) ( P06512 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Has body mass index ( BMI ) 19 34 kg/m^2 , inclusive Has mild severe CRI dialysis ( Participants normal renal function match subject renal impairment ) Clinical laboratory test , electrocardiogram , vital sign within normal range Free clinically significant disease would interfere study evaluation ( except relate his/her renal disease comorbid condition ) Females pregnant , intend become pregnant ( within 3 month end study ) , nursing/breastfeeding Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug Had renal transplant dialysis Has history infectious disease within 4 week Is positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) Has donate blood blood transfusion past 60 day Has demonstrate allergic reaction ( eg , food , drug , atopic reaction asthmatic episode ) could interfere ability participate trial Has history malignancy Has evidence suicidality risk selfharm harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>